Milestone Pharmaceuticals – STANFORD BIODESIGN NEW ARRHYTHMIA TECHNOLOGIES RETREAT | Milestone Pharmaceuticals, Inc.

Milestone Pharmaceuticals – STANFORD BIODESIGN NEW ARRHYTHMIA TECHNOLOGIES RETREAT

May 18, 2023

Supporting Materials

Intranasal Etripamil for the Potential Acute Treatment of Supraventricular Tachycardia and Atrial Fibrillation with Rapid Ventricular Rate 1.5 MB

Print Page

RSS Feeds

Email Alerts

Investor Contact

Search